Qu Jieming

[Expert Profile] Qu Jieming, Chief Physician, Professor, Doctoral Supervisor, is an authoritative expert in pulmonary and critical care medicine in China, working at Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. He has long been dedicated to clinical diagnosis, treatment, and scientific research of difficult pulmonary infections, drug-resistant tuberculosis, and other respiratory infectious diseases, and is an important leading figure in respiratory medicine in China.

[Education & Career] Professor Qu Jieming graduated from Shanghai Second Medical University (now Shanghai Jiao Tong University School of Medicine), completed systematic clinical training at Ruijin Hospital, and further studied at famous international respiratory and infection centers. He has long served as President of Ruijin Hospital and Director of the Department of Pulmonary and Critical Care Medicine, holding important academic positions including Vice Chair of the Respiratory Diseases Branch of the Chinese Medical Association. He has presided over projects including the National Key R&D Program, and is a discipline leader in the fields of respiratory infection and critical care in China.

[Areas of Expertise] Professor Qu specializes in the diagnosis and treatment of difficult pulmonary infections (severe pneumonia, pneumonia in immunocompromised hosts, etc.), drug-resistant tuberculosis and non-tuberculous mycobacterial disease, as well as comprehensive treatment of respiratory critical illness. He has extensive experience in precise etiological diagnosis of pulmonary infections, standardized application of antimicrobial agents, and individualized treatment of drug-resistant bacterial infections. He excels at managing difficult pulmonary infection cases of "recurrent fever and non-resolving imaging findings," helping numerous patients identify pathogens and effectively control infections.

[Academic Achievements & Industry Contributions] Professor Qu has led a series of clinical studies on pulmonary infections and drug-resistant tuberculosis, systematically evaluating the pathogen spectrum and drug resistance trends of pulmonary infections in Chinese populations, and exploring the clinical value of rational antimicrobial use and novel diagnostic techniques, with findings published in authoritative domestic and international journals. He has led the development of Chinese pulmonary infection-related diagnosis and treatment guidelines and expert consensus statements, actively promoted rational antimicrobial use and standardized respiratory critical care treatment, and organized nationwide pulmonary and critical care specialty training, making important contributions to improving the diagnosis and treatment level of pulmonary infections in China.

[Clinical Practice & Outstanding Contributions] For decades on the front lines of pulmonary and critical care medicine, Professor Qu has treated tens of thousands of pulmonary infection and critical care patients, successfully managing numerous severe pneumonia and drug-resistant tuberculosis patients. Leading his team, he has established a comprehensive respiratory critical care treatment system, and has repeatedly participated in medical treatment efforts for major public health events. He has been repeatedly recognized as an outstanding discipline leader, and is deeply trusted by patients and respected by peers alike. He is an outstanding expert in the field of pulmonary and critical care medicine in China.

[Honors & Reputation] Professor Qu Jieming serves as President of Ruijin Hospital, Shanghai Jiao Tong University School of Medicine and Vice Chair of the Respiratory Diseases Branch of the Chinese Medical Association, among other academic positions. He has presided over national-level projects including the National Key R&D Program, and is an authoritative expert in the field of pulmonary and critical care medicine in China. He has profound expertise in the diagnosis and treatment of difficult pulmonary infections, drug-resistant tuberculosis, and respiratory critical care treatment. He has led research on pulmonary infection etiology and drug resistance mechanisms, promoted the standardized application of antimicrobial agents and the construction of respiratory critical care treatment systems, and participated in the development of multiple respiratory infection diagnosis and treatment guidelines. For decades on the clinical front lines, he has successfully treated numerous critical pulmonary infection patients, and is deeply trusted by patients and respected by peers alike.